Travere Therapeutics: The Covert Monopoly in the Kidney Market
Reading Time: 3 minutes
Travere Therapeutics owns the first and only approved therapy for the rare kidney disease FSGS with the active ingredient FILSPARI (Sparsentan), thereby securing a temporary monopoly position in an unoccupied growth market. The successful market entry for the indication IgA nephropathy significantly drives US product growth and swiftly brings the company towards profitability on a normalized basis. Despite excellent exclusivity rights until at least 2037, the stock remains a promising but volatile investment due to a high cluster risk associated...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
